Quadrature Capital Ltd Reduces Stock Holdings in McKesson Corporation $MCK

Quadrature Capital Ltd cut its position in shares of McKesson Corporation (NYSE:MCK) by 36.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 32,489 shares of the company’s stock after selling 19,010 shares during the period. Quadrature Capital Ltd’s holdings in McKesson were worth $25,109,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of MCK. J.W. Cole Advisors Inc. raised its position in McKesson by 35.3% in the third quarter. J.W. Cole Advisors Inc. now owns 5,089 shares of the company’s stock valued at $3,931,000 after purchasing an additional 1,329 shares during the period. Private Wealth Partners LLC grew its holdings in shares of McKesson by 5.6% during the 3rd quarter. Private Wealth Partners LLC now owns 31,841 shares of the company’s stock worth $24,598,000 after purchasing an additional 1,682 shares during the period. AlphaQuest LLC grew its holdings in shares of McKesson by 91.2% during the 3rd quarter. AlphaQuest LLC now owns 1,767 shares of the company’s stock worth $1,365,000 after purchasing an additional 843 shares during the period. CW Advisors LLC increased its position in shares of McKesson by 282.5% during the 2nd quarter. CW Advisors LLC now owns 11,008 shares of the company’s stock worth $8,067,000 after purchasing an additional 8,130 shares during the last quarter. Finally, Envestnet Asset Management Inc. raised its holdings in McKesson by 12.4% in the 3rd quarter. Envestnet Asset Management Inc. now owns 330,647 shares of the company’s stock valued at $255,438,000 after buying an additional 36,451 shares during the period. 85.07% of the stock is currently owned by institutional investors and hedge funds.

McKesson Price Performance

Shares of McKesson stock opened at $943.88 on Friday. The stock has a market capitalization of $115.62 billion, a price-to-earnings ratio of 27.15, a price-to-earnings-growth ratio of 1.50 and a beta of 0.38. The business has a 50-day moving average of $891.54 and a 200 day moving average of $822.52. McKesson Corporation has a 12 month low of $637.00 and a 12 month high of $999.00.

McKesson (NYSE:MCK) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $9.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $9.19 by $0.15. The company had revenue of $106.16 billion for the quarter, compared to analyst estimates of $105.98 billion. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. The business’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $8.03 earnings per share. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. Equities research analysts anticipate that McKesson Corporation will post 32.77 earnings per share for the current year.

McKesson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 1st. Investors of record on Monday, March 2nd will be paid a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Monday, March 2nd. McKesson’s dividend payout ratio is presently 9.43%.

Analyst Ratings Changes

A number of research analysts have commented on MCK shares. Barclays upped their target price on shares of McKesson from $960.00 to $1,050.00 and gave the company an “overweight” rating in a research report on Wednesday, February 18th. TD Cowen boosted their price target on shares of McKesson from $1,000.00 to $1,012.00 and gave the company a “buy” rating in a research note on Thursday, February 5th. Raymond James Financial set a $970.00 price objective on shares of McKesson in a report on Thursday, March 5th. Robert W. Baird set a $968.00 price objective on shares of McKesson in a research report on Wednesday, January 14th. Finally, Mizuho lifted their target price on shares of McKesson from $880.00 to $885.00 and gave the company a “neutral” rating in a report on Thursday, February 5th. Thirteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, McKesson presently has a consensus rating of “Moderate Buy” and an average price target of $960.93.

Insider Activity at McKesson

In other news, EVP Michele Lau sold 2,725 shares of the company’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $990.00, for a total transaction of $2,697,750.00. Following the sale, the executive vice president owned 3,247 shares of the company’s stock, valued at approximately $3,214,530. This represents a 45.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Napoleon B. Rutledge, Jr. sold 328 shares of the stock in a transaction on Friday, February 6th. The shares were sold at an average price of $955.00, for a total value of $313,240.00. The SEC filing for this sale provides additional information. Insiders sold 3,868 shares of company stock worth $3,743,820 over the last 90 days. 0.08% of the stock is currently owned by corporate insiders.

McKesson Company Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.